David Witt, MD

A Q&A session with the expert panel.

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.

Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.

David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.

Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).